Neuron23

D轮

Neuron23 Inc, owned by Origenis GmbH operates as a biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. The company leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases, providing patients with the right medicines suffering from genetic disorders.In March 2022, Neuron23 Inc closed a $100 million Series C financing round led by SoftBank Vision Fund 2, bringing the company's total financing to $213.5 million.In December 2020, the company announced that it had closed USD 113.5 million Series A (USD 33.5 million) and B (USD 80 million) financing. The Series A was led by Westlake Village BioPartners, and Kleiner Perkins, and Series B was led by Redmile Group. Other Series B investors include Westlake Village BioPartners, Kleiner Perkins, Cowen Healthcare Investments, Acorn

https://neuron23.com/

470305

基本信息

公司全称

Neuron23 Inc
类型

遗传疾病治疗用小分子药物研发商
产业领域

医药研发/制造、化学&生物药
公司人数

51~100人
地址

681 Gateway Blvd. 3rd Floor SOUTH SAN FRANCISCO CALIFORNIA 94080; US; Telephone: +13104038951;
联系电话

310-403-8951
邮箱

info.mail@neuron23.com
成立时间

2018-01-01

投融资

2025-06-24

D轮

Westlake Village BioPartners

软银愿景基金

Redmile Group

Blue Owl Capital

Kleiner Perkins

HBM Healthcare

Acorn Bioventures
2022-03-30

C轮

Westlake Village BioPartners

HBM Partners

Perceptive Advisors

Cowen Healthcare Investments

Kleiner Perkins

软银愿景基金

Redmile Group

Surveyor Capital

Acorn Bioventures
2020-12-16

B轮

Redmile Group

Surveyor Capital

Perceptive Advisors

HBM Partners

Acorn Bioventures

Cowen Healthcare Investments

Kleiner Perkins

Westlake Village BioPartners
2020-12-16

A轮

Kleiner Perkins

Westlake Village BioPartners
加载更多

Neuron23

基本信息

投融资

相关投融资企业